TSX Recap: What Happened to Canadian Stocks Yesterday?

The equity markets, including the TSX, experienced another day in the red, as macroeconomic sluggishness weighs on investors.

| More on:
Knowledge concept with quote written on wooden blocks

Image source: Getty Images

The S&P/TSX Composite Index fell 0.2% yesterday. Comparatively, the S&P 500, Dow Jones, and NASDAQ 100 fell by 0.4%, 0.4%, and 0.3%, respectively. It was the fourth consecutive day of decline for major indices, as market participants continue to sweat over the deceleration of economic growth.

According to a recent federal reserve report, for the month of August, sectors such as manufacturing, transportation, residential real estate, and nonfinancial services reported strong numbers, while economic activity moderated in sectors such as outdoor dining, travel, and tourism due to the rising number of infections caused by the Delta variant.

Auto sales remained soft due to the ongoing chip shortages that have impacted manufacturers all around the world.

Bank of Canada maintains policy rates

The Bank of Canada disclosed that it remains optimistic with regards to economic recovery by the end of 2021, despite ongoing weakness in global economies. Canada’s central bank explained that while the second quarter of 2021 saw a spike in consumer spending due to the relaxation of several restrictions, there are supply chain inefficiencies that restrict certain sectors.

This also suggests that the bond tapering process remains on track, which might result in a further decline in equity markets including the TSX. The overnight benchmark rate was unchanged at 0.25%, and the Bank of Canada confirmed it will continue to purchase around $2 billion of Canadian government bonds each week. As economic recovery gains pace, these asset acquisitions will also experience a decline.

The report stated, “The Bank’s QE program continues to reinforce this commitment and keep interest rates low across the yield curve. Decisions regarding future adjustments to the pace of net bond purchases will be guided by governing council’s ongoing assessment of the strength and durability of the recovery. We will continue to provide the appropriate degree of monetary policy stimulus to support the recovery and achieve the inflation objective.”

Canada Goose stock might remain volatile

Shares of luxury parka manufacturer Canada Goose (TSX:GOOS)(NYSE:GOOS) gained over 1.4% yesterday after they fell over 5.5% on Wednesday, as the company was fined by China for misleading customers in ads. According to Shanghai’s market regulator, Canada Goose claimed it used “the warmest material from Hutterite,” which is a region that is popular for producing some of the world’s most high-end goose down.

However, Canada Goose allegedly misinformed customers, as its products are manufactured with other materials. Canada Goose was fined just $71,000, but this development once again puts the focus on strained relations between China and Canada.

Cannabis stocks decline once again

Canadian cannabis stocks continued to underperform the markets on September 9. Shares of Canopy Growth, Aurora Cannabis, and Charlotte’s Web Holdings fell by 0.9%, 0.3%, and 1.8% respectively, yesterday after CNN warned marijuana users that smoking, vaping, or even eating cannabis (read: edibles) may increase the risk of a heart attack significantly. CNN claimed these risks were part of a report published by the Canadian Medical Association Journal.

The report studied 33,000 adults between the age of 18 and 44 and noticed that marijuana users below the age of 45 are twice as likely to suffer a heart attack.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Charlotte's Web Holdings. The Motley Fool recommends Canada Goose Holdings and Charlotte's Web.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »